Log in

Request for Proposal (RFP) Shared Management of Psoriatic Arthritis

09 May 2017 11:25 AM | SACME (Administrator)

Request for Proposal (RFP)
Shared Management of Psoriatic Arthritis

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Date RFP Issued: May 8, 2017

Clinical Area: Psoriatic Arthritis

Link to full RFP: Shared Management of Psoriatic Arthritis

LOI Due Date: June 23, 2017

Specific Area of Interest:   Evidence indicates that many patients with Psoriatic Arthritis (PsA) remain undiagnosed, and those who have been diagnosed are not receiving optimal care. It is our intent to support projects that focus on the coordinated management and identification of patients with psoriatic arthritis (PsA) by both rheumatology and dermatology healthcare professionals. 

Patients with Psoriatic Arthritis experience symptoms that involve both the skin and the joints, impacting their quality of life. Given the nature of the disease, patients may seek care from both dermatologists and rheumatologists, as the disease progresses through periods of flare and remission. A collaborative approach to treatment by a combined team of rheumatology and dermatology clinicians allows for a unique blend of expertise and provides the opportunity for comprehensive care for the PsA patient.

It is expected that projects will be evidence-based and the proposed evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority.

Refer to complete details in the Full RFP document. Questions regarding this RFP should be directed to amanda.solis@pfizer.com.

Powered by Wild Apricot Membership Software